- Home
- CLDI vs GDTC Comparison
CLDI vs GDTC Comparison
Compare CLDI & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- GDTC
- Stock Information
- Founded
- CLDI 2014
- GDTC 2018
- Country
- CLDI United States
- GDTC Singapore
- Employees
- CLDI N/A
- GDTC N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- GDTC Health Care
- Exchange
- CLDI Nasdaq
- GDTC Nasdaq
- Market Cap
- CLDI 35.2M
- GDTC 29.4M
- IPO Year
- CLDI N/A
- GDTC 2023
- Fundamental
- Price
- CLDI $1.05
- GDTC $2.80
- Analyst Decision
- CLDI Strong Buy
- GDTC Buy
- Analyst Count
- CLDI 3
- GDTC 1
- Target Price
- CLDI $16.67
- GDTC $5.00
- AVG Volume (30 Days)
- CLDI 2.7M
- GDTC 17.5K
- Earning Date
- CLDI 03-14-2025
- GDTC 01-01-0001
- Dividend Yield
- CLDI N/A
- GDTC N/A
- EPS Growth
- CLDI N/A
- GDTC N/A
- EPS
- CLDI N/A
- GDTC N/A
- Revenue
- CLDI N/A
- GDTC $330,254.00
- Revenue This Year
- CLDI N/A
- GDTC $14.71
- Revenue Next Year
- CLDI N/A
- GDTC N/A
- P/E Ratio
- CLDI N/A
- GDTC N/A
- Revenue Growth
- CLDI N/A
- GDTC N/A
- 52 Week Low
- CLDI $0.58
- GDTC $1.20
- 52 Week High
- CLDI $16.80
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- CLDI 45.04
- GDTC 55.34
- Support Level
- CLDI $1.16
- GDTC $2.50
- Resistance Level
- CLDI $1.30
- GDTC $2.77
- Average True Range (ATR)
- CLDI 0.24
- GDTC 0.23
- MACD
- CLDI 0.01
- GDTC 0.01
- Stochastic Oscillator
- CLDI 40.10
- GDTC 76.27
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.